Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nanatinostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Viracta Therapeutics Reports Q2 2024 Financial Results And Business Update
    Viracta Therapeutics Reports Q2 2024 Financial Results And Business Update

    14 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/14/2929942/0/en/Viracta-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    14 Aug 2024
    Share Share
    Viracta Positive Nana-val NAVAL-1 EBV+ PTCL Topline Results
    Viracta Positive Nana-val NAVAL-1 EBV+ PTCL Topline Results

    15 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/15/2862733/0/en/Viracta-Therapeutics-Announces-Positive-Topline-Nana-val-Results-from-Stage-1-of-the-NAVAL-1-Trial-in-Patients-with-Relapsed-or-Refractory-Epstein-Barr-Virus-Positive-EBV-Periphera.html

    GLOBENEWSWIRE
    15 Apr 2024
    Share Share
    Viracta Therapeutics Announces Orphan Drug Designation Granted
    Viracta Therapeutics Announces Orphan Drug Designation Granted

    24 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/viracta-therapeutics-announces-orphan-drug-designation-granted-for-the-treatment-of-t-cell-lymphoma-301083191.html

    PRNEWSWIRE
    24 Jun 2020
    Share Share